↓ Skip to main content

Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome

Overview of attention for article published in BMC Pharmacology and Toxicology, March 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
21 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome
Published in
BMC Pharmacology and Toxicology, March 2015
DOI 10.1186/s40360-015-0005-1
Pubmed ID
Authors

Masahiro Inoue, Manabu Shoji, Naomi Shindo, Kazunori Otsuka, Masatomo Miura, Hiroyuki Shibata

Abstract

Chemotherapy-induced nausea and vomiting is one of the most influential factors that affect patient quality of life; thus, preventing this adverse event could lead to better patient outcome. Standard preventive guidelines for antiemetic treatment have already been established based on the emetogenicity of chemotherapeutic agents. It is important that compliance with in-house guidelines and their effect on patient outcome is monitored. In 3 years since the Akita university hospital antiemetic guidelines were outlined, we assessed the incidence of chemotherapy-induced nausea and vomiting using the antiemesis tool of the Multinational Association of Supportive Care in Cancer. Compliance of the guidelines was extracted from the hospital clinical record, and the chemotherapy-induced nausea and vomiting was examined by the patient reported outcome. Seventy-three patients answered the questionnaire. The overall compliance rate with the guidelines for early nausea and vomiting was 98.6% and with the delayed nausea and vomiting was 87.7%. The complete response rate for the early and delayed chemotherapy-induced nausea and vomiting was 77.8% and 73.8%, respectively. The overall relative risk of early nausea and vomiting was 0.22 (P < 0.05), whereas the relative risk for delayed nausea and vomiting was 2.09 (P < 0.05). Breakthrough vomiting was observed in 3 cases in the low-risk group only. These data suggest that delayed nausea and vomiting is difficult to prevent, particularly in the low-risk group. Further, it seems that the individual sensitivity for emetogenicity might differ among patients. In addition to standard prevention guidelines based on emetogenicity, individual care based on patient reports should be considered for the complete prevention of chemotherapy-induced nausea and vomiting.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 4 19%
Student > Master 3 14%
Student > Bachelor 3 14%
Professor > Associate Professor 2 10%
Professor 1 5%
Other 3 14%
Unknown 5 24%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 4 19%
Medicine and Dentistry 4 19%
Nursing and Health Professions 3 14%
Agricultural and Biological Sciences 1 5%
Biochemistry, Genetics and Molecular Biology 1 5%
Other 2 10%
Unknown 6 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2015.
All research outputs
#3,499,657
of 4,946,953 outputs
Outputs from BMC Pharmacology and Toxicology
#111
of 142 outputs
Outputs of similar age
#107,573
of 146,790 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#5
of 6 outputs
Altmetric has tracked 4,946,953 research outputs across all sources so far. This one is in the 16th percentile – i.e., 16% of other outputs scored the same or lower than it.
So far Altmetric has tracked 142 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 146,790 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.